Want to see SE:BIOG.B full AI Analyst Report?
Top Page
BioGaia AB
(BIOG.B)
Select Model
Select Model
Rating:79Outperform
Price Target:
kr143.00
▲(23.81% Upside)
Action:Reiterated
Date:10/27/26
The score is driven primarily by strong financial quality (high margins, strong ROE, and near-zero leverage), supported by positive technical momentum (price above key moving averages and positive MACD). The main constraint is valuation, with a relatively high P/E and only a modest dividend yield, alongside some recent softening in margins and free cash flow.
Positive Factors
High profitability
BioGaia’s consistently high gross and EBIT margins indicate a profitable business model with substantial operating economics. This profitability can support investment in products, clinical positioning, and distribution while providing resilience if revenue growth moderates over the next several quarters.
Negative Factors
Free cash flow deterioration
Although cash conversion remains healthy in absolute terms, the recent decline in free cash flow weakens the trend in internally generated funds. If sustained, this could reduce the capacity available for product development, distributions, or other strategic uses of cash.
Read all positive and negative factors
Positive Factors
Negative Factors
High profitability
BioGaia’s consistently high gross and EBIT margins indicate a profitable business model with substantial operating economics. This profitability can support investment in products, clinical positioning, and distribution while providing resilience if revenue growth moderates over the next several quarters.
Read all positive factors
BioGaia AB (BIOG.B) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr12.18B
Dividend Yield1.37%
Average Volume (3M)212.25K
Price to Earnings (P/E)31.1
Beta (1Y)0.34
Revenue Growth13.13%
EPS Growth23.94%
CountrySE
Employees251
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)3.87
Shares Outstanding98,497,170
10 Day Avg. Volume299,480
30 Day Avg. Volume212,253
Financial Highlights & Ratios
PEG Ratio-6.22
Price to Book (P/B)8.17
Price to Sales (P/S)6.98
P/FCF Ratio35.46
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)4.02
Revenue Forecast (FY)kr1.69B
BioGaia AB Business Overview & Revenue Model
Company Description
BioGaia AB (publ), a Swedish enterprise founded in 1990 and headquartered in Stockholm, is dedicated to the worldwide development, marketing, and distribution of probiotic products renowned for their scientifically proven health advantages. The co...
How the Company Makes Money
BioGaia makes money mainly by commercializing probiotic products and probiotic ingredients built around its Lactobacillus reuteri strains. Its revenue model typically includes: (1) Sales of finished consumer products: BioGaia sells branded probiot...
BioGaia AB Financial Statement Overview
Summary
Income Statement
86
Very Positive
Balance Sheet
94
Very Positive
Cash Flow
78
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.65B | 1.54B | 1.42B | 1.30B | 1.10B | 785.11M |
| Gross Profit | 1.20B | 1.13B | 1.03B | 950.19M | 801.93M | 582.95M |
| EBITDA | 496.12M | 454.33M | 488.29M | 494.92M | 476.89M | 276.86M |
| Net Income | 391.55M | 332.76M | 351.39M | 365.35M | 373.77M | 196.27M |
Balance Sheet | ||||||
| Total Assets | 1.45B | 1.60B | 2.03B | 2.33B | 2.21B | 2.13B |
| Cash, Cash Equivalents and Short-Term Investments | 518.27M | 801.31M | 1.22B | 1.54B | 1.49B | 1.48B |
| Total Debt | 0.00 | 6.90M | 7.10M | 8.80M | 16.01M | 9.81M |
| Total Liabilities | 229.68M | 283.59M | 310.07M | 305.54M | 241.55M | 250.69M |
| Stockholders Equity | 1.22B | 1.31B | 1.72B | 2.03B | 1.97B | 1.88B |
Cash Flow | ||||||
| Free Cash Flow | 258.38M | 302.97M | 359.06M | 377.25M | 301.03M | 215.50M |
| Operating Cash Flow | 284.45M | 306.57M | 373.22M | 425.96M | 318.94M | 221.88M |
| Investing Cash Flow | -26.21M | -3.34M | -14.07M | -50.94M | -18.14M | -126.97M |
| Financing Cash Flow | -476.20M | -709.87M | -689.72M | -308.42M | -313.59M | -81.85M |
BioGaia AB Technical Analysis
Positive
115.50
Price Trends
115.78
Positive
116.31
Positive
115.21
Positive
Market Momentum
2.11
Positive
51.19
Neutral
4.12
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:BIOG.B, the sentiment is Positive. The current price of 115.5 is below the 20-day moving average (MA) of 121.17, below the 50-day MA of 115.78, and above the 200-day MA of 115.21, indicating a neutral trend. The MACD of 2.11 indicates Positive momentum. The RSI at 51.19 is Neutral, neither overbought nor oversold. The STOCH value of 4.12 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:BIOG.B.
BioGaia AB Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
79 Outperform | kr12.18B | 31.11 | 31.08% | 1.37% | 13.13% | 23.94% | |
58 Neutral | kr3.04B | 35.19 | 1.24% | 1.47% | 2.73% | 36.67% | |
58 Neutral | kr9.59B | 39.05 | ― | 0.65% | 9.35% | -91.93% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
49 Neutral | kr371.09M | -28.83 | ― | ― | 54.37% | 52.22% | |
44 Neutral | kr551.01M | -12.24 | ― | ― | 3.26% | 16.82% |
* General Sector Average
SE:BIOG.B
BioGaia AB
120.40
22.98
23.59%
SE:MVIR
Medivir AB
1.55
1.01
187.04%
SE:SECARE
Swedencare AB
19.00
-19.00
-50.00%
SE:APOTEA
Apotea AB
92.15
9.90
12.03%
SE:ENZY
Enzymatica AB
2.27
0.34
17.62%
SE:CLBIO
Corline Biomedical AB
14.20
-5.60
-28.28%
BioGaia AB Corporate Events
BioGaia boosts margins and expands probiotic reach in Q3 2026
Oct 22, 2026
BioGaia AB reported strong growth for the third quarter of 2026, with net sales rising 23% to SEK 400.4 million and operating profit up 54%, lifting the operating margin to 33%. The Pediatrics and Adult Health segments both delivered double-digit ...
BioGaia names Nomination Committee for 2027 AGM
Oct 15, 2026
BioGaia AB has appointed its Nomination Committee for the 2027 Annual General Meeting, based on the ownership structure as of June 30, 2026 and in line with a previous AGM decision. The committee includes representatives from major shareholders An...
BioGaia Sets October 22 Date for Q3 2026 Results and Investor Briefing
Oct 9, 2026
BioGaia AB will publish its financial report for the third quarter of 2026 on October 22 at around 8:00 AM CEST, followed by a live audiocast at 9:30 AM CEST where CEO Theresa Agnew and CFO Alexander Kotsinas will present the results and answer qu...
BioGaia to Outline Long-Term Strategy at London Capital Markets Day
Sep 16, 2026
BioGaia AB will host a Capital Markets Day in London on December 8, 2026, offering both in-person attendance and a live webcast to reach a broad investor base. The event underscores the company’s intent to deepen engagement with the financia...
BioGaia launches clinically proven colon health probiotic Colus
Sep 9, 2026
BioGaia AB is expanding its adult gut health portfolio with BioGaia Colus, a new probiotic supplement targeting colon health using the proprietary L. reuteri BG-R59 strain and delayed-release vegan capsules designed for delivery to the lower gastr...
BioGaia Deepens Iberian Partnership With Recordati to Drive Probiotic Growth
Aug 31, 2026
BioGaia AB, a Swedish probiotics specialist with a global footprint and a focus on gut, immune and oral health, is deepening its commercial ties in Southern Europe. The company relies on local distribution partners such as Recordati to reach more ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.